Key result
Nanoencapsulated imatinib and/or hesperidin significantly reduced tumor volume, weight, cardiac markers, and MDR-1 gene expression compared to free conventional treatment in SEC-bearing mice.
Why the study?
There is a demand for new breast cancer treatments, motivating evaluation of nanoencapsulated imatinib mesylate and hesperidin to enhance anticancer activity and reduce imatinib cardiotoxicity.
Does nanoencapsulation of imatinib and hesperidin enhance anticancer activity and reduce cardiotoxicity in SEC-bearing mice?
RCT (n=80)
Randomly divided
Does nanoencapsulation of imatinib and hesperidin enhance anticancer activity and reduce cardiotoxicity in SEC-bearing mice?
Nanoencapsulation of imatinib and hesperidin in PLGA polymer enhances anticancer efficacy and ameliorates imatinib-induced cardiotoxicity in a murine breast cancer model.
May enhance imatinib tolerability in preclinical models; leaves open human translation.
There is a great demand to introduce new approaches into cancer treatment field due to incidence of increased breast cancer all over the world. The current study was designed to evaluate the role of imatinib mesylate (IM) and/or hesperidin (HES) nanoparticles alone or in combination in enhancing the anticancer activity and to investigate the ability of nanoencapsulation to reduce cardiotoxicity of IM in solid Ehrlich carcinoma (SEC)-bearing mice. IM and HES were loaded into PLGA (poly(lactic-co-glycolic acid) polymer. SEC was induced in female albino mice as a model for experimentally induced breast cancer. Mice were randomly divided into eight groups (n = 10). On day 28 from tumor inoculation, mice were sacrificed and blood samples were collected in heparinized tubes for hematological studies, biochemical determination of lactate dehydrogenase (LDH), and glutamic oxaloacetic transaminase (SGOT) levels. In addition, tumor and cardiac tissues were utilized for histopathological examination as well as determination of MDR-1 gene expression. Immunohistochemical staining of BAX and BCL-2 was done. Nano IM- and/or Nano HES-treated groups showed a significant reduction in tumor volume, weight, hematological, cardiac markers, and tumor MDR-1 gene downregulation compared to free conventional treated groups. In conclusion, the use of HES as an adjuvant therapy with IM could improve its cytotoxic effects and limit its cardiac toxicity. Furthermore, nanoencapsulation of IM and/or HES with PLGA polymer showed a remarkable anticancer activity.
No takes yet. Share an insight, caveat, or question.
El‐Sisi et al. (2020) conducted an RCT in Solid Ehrlich carcinoma (breast cancer model) (n=80). Nanoencapsulated imatinib mesylate and/or hesperidin vs. Free conventional treatment was evaluated on Tumor volume, weight, hematological and cardiac markers, and tumor MDR-1 gene expression. Nanoencapsulated imatinib and/or hesperidin significantly reduced tumor volume, weight, cardiac markers, and MDR-1 gene expression compared to free conventional treatment in SEC-bearing mice.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: